Nivaquine is Produced on Sanofi Industrial Site in Morocco and is Not Subject of Any Export Activity

Rabat - Nivaquine (chloroquine sulfate), recommended in the curative and preventive treatment of malaria, is produced on the industrial site of Sanofi in Morocco and is not the subject of any export activity, said on Sunday the pharmaceutical group Sanofi Morocco. This statement comes in reaction to an article on Radio France Internationale (RFI) and run by media in Morocco, in which it is mentioned that the stock of Nivaquine bought by the Moroccan state was intended for sub-Saharan Africa.

The group emphasized that Nivaquine has a marketing authorization (AMM) valid "only for the Moroccan market". It noted that upon receipt of the request from the Ministry of Health, Sanofi has delivered all of its stock of Nivaquine and Plaquenil (hydroxychloroquine), indicated for the treatment of rheumatoid arthritis and collagen diseases, added the group. Sanofi Maroc follows very closely, in collaboration with the Ministry of Health, the evolution of clinical trials concerning these two molecules: chloroquine sulfate and hydroxychloroquine.